Gadeta B.V.   Report issue

For profit Phase 1
Founded: Utrecht Netherlands (2015)
Status: Acquired by Gilead Sciences (2018)

Organization Overview

First Clinical Trial
2020
NCT04688853
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Gadeta B.V.

Active Ingredients

Drugs in Phase 1 Trials (1)

teg002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1